Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
|Articles|July 2, 2016
- Pharmaceutical Technology-07-02-2016
- Volume 40
- Issue 7
Double Planetary Mixer for Deaeration of Viscous Formulations
The Double Planetary Mixer (DPM) from Ross, Charles & Son can be used for single-pot mixing and deaeration of viscous formulations such as thick pastes, putties, gels, and other semi-solid products.
The Double Planetary Mixer (DPM) from Ross, Charles & Son can be used for single-pot mixing and deaeration of viscous formulations such as thick pastes, putties, gels, and other semi-solid products. The mixer is equipped with high viscosity blades allowing it to process highly filled and high density applications up to six million centipoise in viscosity. This heavy-duty mixer features a high-precision gearbox enabling quiet operation as well as reduced wear and tear.
The DPM’s stainless steel wetted surfaces are 150-grit finish and electropolished with a dust shield to prevent product dust and splash from getting into the gearbox. The planetary high viscosity blades orbit the vessel at 7 to 30 rpm. Additionally, a detachable sidewall scraper arm is supplied for sticky applications. A dual-post hydraulic lift with safety locking mechanism raises/lowers the agitators to and from the mixing position. The mixer’s change can design allows the use of multiple vessels: two 200-gallon mix cans supplied with the DPM-200 include a 50-psig dual-zone spiral baffled jacket, glass wool insulation, stainless steel sheathing, RTD thermocouple, caster wheels, and tow hitch.
Articles in this issue
over 10 years ago
FDA and Manufacturers Intensify Concerns about Data Integrityover 10 years ago
Planning a Biologics Facility Start Upover 10 years ago
Solid-Dosage Packaging Trendsover 10 years ago
Quality System for a Regulatory Affairs Departmentover 10 years ago
Data Integrity Challenges in Manufacturingover 10 years ago
Bio/Pharma Funding Challenges Could Hurt CDMOs in 2017over 10 years ago
Cleaning Bioreactors and Fermenters with CIP Systemsover 10 years ago
Maximize Efficiency in Tooling Maintenanceover 10 years ago
Recognizing Pharma Industry Excellenceover 10 years ago
Expanding the Chiral ToolboxRelated to this article
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Trending on Pharmaceutical Technology
1
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
2
CPHI Milan: Packaging and Delivery Decisions Must Reflect Real-World Care
3
Manufacturing Intelligence: Organoids, Organ-on-a-Chip, and the Trust Gap
4
Complying with International Pharmacopoeias
5